LY2963016 + Lantus
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
May 1, 2012 → Jul 1, 2012
NCT ID
NCT01600950About LY2963016 + Lantus
LY2963016 + Lantus is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT01600950. Target conditions include Diabetes Mellitus, Type 1.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01634165 | Phase 1 | Completed |
| NCT01600950 | Phase 1 | Completed |
| NCT01476345 | Phase 1 | Completed |
| NCT01374178 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1